Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash from Financing Activities for 6 consecutive years, with $116000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 79.58% to $116000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $18.5 million, a 94.57% decrease, with the full-year FY2024 number at $337.2 million, up 115.04% from a year prior.
  • Cash from Financing Activities was $116000.0 for Q3 2025 at 4D Molecular Therapeutics, down from $601000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $318.8 million in Q1 2024 to a low of -$847000.0 in Q1 2021.
  • A 5-year average of $36.2 million and a median of $2.0 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 117.74% in 2021, then surged 261138.0% in 2023.
  • 4D Molecular Therapeutics' Cash from Financing Activities stood at $116.1 million in 2021, then crashed by 98.24% to $2.0 million in 2022, then skyrocketed by 132.75% to $4.8 million in 2023, then crashed by 87.38% to $601000.0 in 2024, then crashed by 80.7% to $116000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Cash from Financing Activities are $116000.0 (Q3 2025), $601000.0 (Q4 2024), and $568000.0 (Q3 2024).